Recent MSK Discoveries & Advances

Memorial Sloan Kettering researchers are relentlessly exploring every aspect of cancer — from basic investigations of cells and molecules to clinical trials of new treatments and population-wide studies of the disease. While our core mission is to translate this knowledge into new strategies to control cancer, many of our investigators are also making scientific progress against other diseases and conditions.

Below are some examples of discoveries and advances that recently were made in our laboratories and clinics, and featured in our news stories.

and/or
383 News Items found
Various kinds of nuts
In the Clinic
People who maintain a healthy lifestyle after surgery and chemotherapy for colon cancer are more likely to have a favorable outcome after treatment.
Left-handed and right-handed KRas molecules
In the Lab
MSK chemists are focusing on developing small-molecule drugs to target KRas, an important cancer protein.
Scientists at the Sloan Kettering Institute are learning why some immune cells are stubbornly hard to revive with immunotherapy.
In the Lab
By looking at how DNA is packaged in cells, scientists are teasing apart a long-standing conundrum about the immune response to cancer.
Mount Rushmore viewed through face-detection software.
Taking a cue from smartphone technology, scientists are using face-recognition algorithms to improve RNA interference.
A cell in the process of dividing
In the Lab
MSK researchers are learning how cells are able to recognize and correct errors that occur during cell division.
An illustration of CRISPR-Cas9
In the Lab
A freely accessible software program provides researchers with an easy way to optimize a popular genome-editing tool.
Image of liver with tumors
In the Clinic
A retrospective study from MSK has found that colorectal cancer patients with liver metastases live an average of two years longer when they receive an additional treatment called hepatic arterial infusion (HAI).
photo of blood vials
Finding
Why do some patients respond to immunotherapy while others do not? Blood may hold the answer.
immune cells
Finding
Leukemia patients may do better on CAR T cell therapy when they are treated early, before their disease relapses.
David Hyman and Robin Gillespie
Finding
Neratinib, which targets mutations that drive cancer growth, is showing promise for treating several types of cancer.